- Home
- KULR vs ANTX Comparison
KULR vs ANTX Comparison
Compare KULR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | ANTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 170.6M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KULR | ANTX |
|---|---|---|
| Price | $3.83 | $4.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 3.1M | 207.7K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,274,028.00 | N/A |
| Revenue This Year | $123.93 | N/A |
| Revenue Next Year | $63.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.00 |
| 52 Week High | $7.49 | $6.91 |
Technical Indicators
Market Signals| Indicator | KULR | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 60.01 |
| Support Level | $3.03 | $1.06 |
| Resistance Level | $4.47 | $5.13 |
| Average True Range (ATR) | 0.51 | 0.37 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 18.25 | 76.64 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.